高级检索

人脐带源间充质干细胞联合肠道益生菌促进小鼠糖尿病创面愈合

Human umbilical cord-derived mesenchymal stem cells combined with intestinal probiotics promote wound healing in diabetic mice

  • 摘要: 探讨人脐带间充质干细胞(human umbilical cord mesenchymal stem cells, hUCMSCs)联合肠道益生菌对糖尿病小鼠皮肤创面愈合的治疗作用及其潜在机制。选取25只C57BL/6J雄性小鼠,通过腹腔注射链脲佐菌素(streptozotocin, STZ)诱导糖尿病并构建背部皮肤创面模型,随后将造模成功的小鼠随机分为5组(n=5),即空白对照组、模型组、hUCMSCs治疗组、益生菌治疗组和hUCMSCs联合益生菌治疗组。分别于第0、3、6、9、12天拍照记录创面愈合情况,并分析各组创面未愈合率的差异;采用HE和Masson染色观察组织病理学变化及胶原沉积;采用CD31免疫荧光染色检测血管新生情况;采用Collagen I免疫组化染色评估I型胶原的形成情况;采用ELISA检测创面组织中促炎因子(TNF-α、IL-1β、IL-6)及抗炎因子(Arg1)的表达水平。结果显示:造模后第12天,各治疗组均观察到创面面积显著减小,其中联合治疗组创面收缩最为明显,愈合速度最快;HE和Masson染色显示,各治疗组均可见上皮化进程加快和胶原组织沉积增多的情况,其中以联合治疗组效果最优;免疫荧光和免疫组化显示,与模型组比较,各治疗组CD31和Collagen I表达明显增多,其中以联合治疗组表达最多;ELISA显示hUCMSCs联合益生菌治疗组Arg1表达量高于其他组,但差异无统计学意义(P>0.05),与模型组比较,各治疗组的TNF-α、IL-1β、IL-6含量均有所降低,其中以联合治疗组含量最少。以上结果初步表明hUCMSCs与肠道益生菌联合治疗可通过促进血管新生、增强胶原沉积、调控炎症微环境等机制协同加速糖尿病小鼠创面愈合,其疗效显著优于单一治疗,该研究为糖尿病足的临床治疗提供了新的潜在策略。

     

    Abstract: The therapeutic effect of human umbilical cord mesenchymal stem cells (hUCMSCs) combined with intestinal probiotics on the wound healing of diabetic mice and its potential mechanism were explored. Twenty-five male C57BL/6J mice were selected and induced to develop diabetes by intraperitoneal injection of streptozotocin (STZ), and a back skin wound model was constructed. Then, the diabetic mice were randomly divided into 5 groups (n=5), namely the blank control group, the model group, the hUCMSCs treatment group, the probiotic treatment group, and the hUCMSCs combined with probiotic treatment group. The wound healing status was photographed and recorded at days 0, 3, 6, 9, and 12, and the differences in the non-healing rate of the wounds in each group were analyzed. HE and Masson staining were used to observe the histological changes and collagen deposition; CD31 immunofluorescence staining was used to detect angiogenesis; Collagen I immunohistochemical staining was used to evaluate the formation of type I collagen; ELISA was used to detect the expression levels of pro-inflammatory factors (TNF-α, IL-1β, IL-6) and anti-inflammatory factor (Arg1) in the wound tissue. The results showed that on the 12th day after modeling, all treatment groups observed a significant reduction in wound area, with the combined treatment group showing the most obvious wound contraction and the fastest healing speed; HE and Masson staining showed that in each treatment group, the process of epithelialization and the deposition of collagen tissue increased, and the combined treatment group had the best effect; immunofluorescence and immunohistochemistry showed that compared with the model group, the expression of CD31 and Collagen I in each treatment group was significantly increased, with the combined treatment group having the most expression; ELISA showed that the Arg1 expression level in the hUCMSCs combined with probiotic treatment group was higher than that in other groups, but the difference was not statistically significant (P>0.05), and compared with the model group, the contents of TNF-α, IL-1β, and IL-6 in each treatment group were all reduced, with the combined treatment group having the lowest content. The above results preliminarily indicate that the combined treatment of hUCMSCs and intestinal probiotics can accelerate the wound healing of diabetic mice through mechanisms such as promoting angiogenesis, enhancing collagen deposition, and regulating the inflammatory microenvironment, and its efficacy is significantly better than single treatment. This study provides a new potential strategy for the clinical treatment of diabetic foot.

     

/

返回文章
返回